IDH1 and acute myeloid leukemia: Small molecule inhibitors of both IDH2 (60) and IDH1 (61, 62) reduce the levels of 2-HG and induce differentiation of AML cells, and were able to produce durable remissions in patients when used as single agents (13, 19, 63).